Advanced Glycation End-Products and Its Receptors in Cancer Progression
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Tumor Microenvironment".
Deadline for manuscript submissions: 31 March 2025 | Viewed by 74
Special Issue Editor
Interests: advanced glycation end products; toxic advanced glycation end products; receptor for advanced glycation end products (RAGEs); glycosaminoglycans; cancer; cancer stem cells (CSCs); tumor immune microenvironment (TME)
Special Issue Information
Dear Colleagues,
Advanced glycation end products (AGEs) are a group of compounds formed when sugars react with proteins and lipids in the body. They have been implicated in various diseases, including cancer, through receptors for AGE (RAGEs), as well as dependent and independent mechanisms. An increasing body of literature implicates AGEs/RAGEs in various hallmarks of cancer, including the tumor immune microenvironment (TME), inflammation and cancer stem cells (CSCs).
In this Special Issue, we aim to explore the latest research findings and advancements in understanding the role of AGEs in cancer. The issue will focus on the biochemistry and clinical detection of AGEs, their clinical relevance and biology, and the molecular mechanism of AGE/RAGE-induced carcinogenesis or therapeutic strategies targeting AGEs/RAGEs in cancer. We especially invite articles examining the role of glycosaminoglycans (GAGs) in regulating AGEs/RAGEs in cancer, as well as CSC biology and the role of AGEs/RAGEs in inflammatory TME and therapeutic targeting thereof.
Dr. Bhaumik B. Patel
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- advanced glycation end products
- toxic advanced glycation end products
- receptor for advanced glycation end products (RAGEs)
- glycosaminoglycans
- cancer
- cancer stem cells (CSCs)
- tumor immune microenvironment (TME)
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
